Myriad Genetics Promotes Nicole Lambert to Chief Operating Officer
14 Dezembro 2021 - 6:05PM
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, today announced the promotion of Nicole
Lambert to chief operating officer (COO). In her new role, she will
continue to report directly to Paul J. Diaz, president and CEO,
Myriad Genetics.
Over a 20-year career at the company, Lambert served in several
senior leadership positions, most recently overseeing Myriad’s
Oncology, Women’s Health and International business units as well
as genetic testing laboratory operations. As COO, she assumes
additional responsibility for accelerating the company’s
transformation and growth plans, elevating products to their full
potential, and implementing operational efficiencies to better
serve patients and healthcare providers.
“Nicole is a proven leader with a deep understanding of our
business and a passion for our mission of providing genetic
insights that improve health and well-being for every individual,”
said Diaz. “She has a unique combination of business, healthcare
and operational experience coupled with strong leadership qualities
and expertise in applying the power of genetics to improve patient
outcomes. Nicole has been instrumental in executing our
transformation to date and will now play an even broader role in
accelerating our progress.”
“Over the past 20 years, I have had the honor of being a part of
this incredibly committed team. I am proud of the level of
excellence that Myriad provides; from accuracy in the laboratory to
care and compassion in our customer service and medical teams,”
said Lambert. “I have seen this impact my own family, and carry
that passion into my new role, as we transform our company with an
intensified focus on operational excellence, innovative science,
and access for all.”
Prior to her career at Myriad, Lambert served as a genetic
counselor at LabCorp. She received her bachelor’s degree in Biology
and Sociology from Boston College and earned her master’s in
genetic counseling from Mt. Sinai School of Medicine at New York
University. She currently serves as a board member of Arcus
Biosciences (NYSE: RCUS).
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision
medicine company dedicated to advancing health and well-being for
all, empowering individuals with vital genetic insights and
enabling healthcare providers to better detect, treat and prevent
disease.
Myriad discovers and commercializes genetic tests that determine
the risk of developing disease, accurately diagnose disease, assess
the risk of disease progression, and guide treatment decisions
across medical specialties where critical genetic insights can
significantly improve patient care and lower healthcare costs. For
more information, visit the Company's
website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice,
MyPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, MyChoice CDx,
EndoPredict, Prequel, Foresight, GeneSight, RiskScore and Prolaris
are trademarks or registered trademarks of Myriad Genetics, Inc. or
its wholly owned subsidiaries in the United States and foreign
countries.
Safe Harbor Statement Safe Harbor Statement
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to accelerating the company’s
transformation and growth plans, elevating products to their full
potential, and implementing operational efficiencies to better
serve patients and healthcare providers; and the company’s
strategic imperatives under the caption “About Myriad Genetics.”
These “forward-looking statements” are management’s present
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those described in the
forward-looking statements. These risks include, but are not
limited to: uncertainties associated with COVID-19, including its
possible effects on the company’s operations and the demand for its
products and services; risks related to the company’s ability to
efficiently and flexibly manage its business amid uncertainties
associated with COVID-19; the risk that sales and profit margins of
the company’s existing molecular diagnostic tests may decline or
that the company may not be able to operate its business on a
profitable basis; risks related to the company’s ability to
generate sufficient revenue from its existing product portfolio or
in launching and commercializing new tests; risks related to
changes in governmental or private insurers’ coverage and
reimbursement levels for the company’s tests or the company’s
ability to obtain reimbursement for its new tests at comparable
levels to its existing tests; risks related to increased
competition and the development of new competing tests and
services; the risk that the company may be unable to develop or
achieve commercial success for additional molecular diagnostic
tests in a timely manner, or at all; the risk that the company may
not successfully develop new markets for its molecular diagnostic
tests, including the company’s ability to successfully generate
revenue outside the United States; the risk that licenses to the
technology underlying the company’s molecular diagnostic tests and
any future tests are terminated or cannot be maintained on
satisfactory terms; risks related to delays or other problems with
operating the company’s laboratory testing facilities; risks
related to public concern over genetic testing in general or the
company’s tests in particular; risks related to regulatory
requirements or enforcement in the United States and foreign
countries and changes in the structure of the healthcare system or
healthcare payment systems; risks related to the company’s ability
to obtain new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks
related to the company’s ability to successfully integrate and
derive benefits from any technologies or businesses that it
licenses or acquires; risks related to the company’s projections
about the potential market opportunity for the company’s products;
the risk that the company or its licensors may be unable to protect
or that third parties will infringe the proprietary technologies
underlying the company’s tests; the risk of patent-infringement
claims or challenges to the validity of the company’s patents;
risks related to changes in intellectual property laws covering the
company’s molecular diagnostic tests, or patents or enforcement, in
the United States and foreign countries; risks related to security
breaches, loss of data and other disruptions, including from
cyberattacks; risks of new, changing and competitive technologies
and regulations in the United States and internationally; the risk
that the company may be unable to comply with financial operating
covenants under the company’s credit or lending agreements; and
other factors discussed under the heading “Risk Factors” contained
in Item 1A of the company’s Transition Report on Form 10-K filed
with the Securities and Exchange Commission on March 16, 2021, as
well as any updates to those risk factors filed from time to time
in the company’s Quarterly Reports on Form 10-Q or Current Reports
on Form 8-K.
Media
Contact:Megan Manzari(385)
318-3718Megan.Manzari@myriad.com |
|
Investor Contact:Nathan Smith(801)
505-5067Nathan.Smith@myriad.com |
Arcus Biosciences (NYSE:RCUS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Arcus Biosciences (NYSE:RCUS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024